The Histology, Immunochemistry, and Microscopy core (HIM Core) of the COBRE provides the COBRE investigators and other cancer researchers in Oklahoma with high quality histology, immunochemistry, and microscopy services. This core is directed by Dr. Fung, who is a board-certified pathologist who has more than 28-years of experience in research with histologic techniques. The HIM Core has a well-equipped laboratory that provides histologic sectioning, conventional staining, immunohistochemistry, immunofluorescence, in situ hybridization, combined immunohistochemistry and in situ hybridization, enzyme histochemistry, and other contemporary staining techniques. Most of these staining procedures are automated in order to maintain a high quality. This core also provides whole slide scanning service supported by image analysis with a choice of multiple algorithms and tissue microarray segmentation softwares. The director of the core also provides technical advice on experimental design and methodologies appropriate for the project. The core also provides training on the use of various microscopes including conventional bright-field, phase- and epifluorescence- microscopy as well as new instruments for live cell imaging. This is the only such facility available in the state of Oklahoma. Established in 2012, under the auspices of Phase I of this COBRE, the core has proven to be critical to meet the scientific needs of the COBRE investigators in addition to catering the needs of other cancer researchers in Oklahoma. During Phase I of this COBRE, 6 COBRE Promising-Junior or target investigators and 64 non-COBRE investigators used this core. The mission of the HIM Core is accomplished under the following three specific aims: 1. Consultation on experimental design and interpretation of results; 2. Histological methods and staining services; and 3. Whole slide scanning, image analysis, and live cell imaging services.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-08
Application #
10017273
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications